AbdelGhaffar, 3,712 patient HCQ late treatment study: 100% lower mortality [p<0.0001] https://c19p.org/abdelghaffar
copied to clipboard
Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study
et al., PLOS ONE, doi:10.1371/journal.pone.0262348
Retrospective 3,712 hospitalized patients in Egypt, showing lower mortality with HCQ treatment in unadjusted results. According to the official treatment protocol, HCQ was recommended with higher risk and/or more serious cases.
|
risk of death, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 238 (0.0%), control 900 of 3,474 (25.9%), NNT 3.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
AbdelGhaffar et al., 1/11/2022, retrospective, Egypt, Africa, peer-reviewed, 17 authors, study period April 2020 - July 2020.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.